A novel finasteride 0.25% topical solution for androgenetic alopecia: Pharmacokinetics and effects on plasma androgen levels in healthy male volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 52, Issue 10, 2014, Pages 842-849

  Caserini, Maurizio ^a   Radicioni, Milko ^b   Leuratti, Chiara ^b   Annoni, Ottavia ^b   Palmieri, Renata ^a  

^a Polichem SA   (Switzerland)

^b Cross Research SA   (Switzerland)

Author keywords

Androgenetic alopecia; Dihydrotestosterone; Finasteride

Indexed keywords

ANDROSTANOLONE; FINASTERIDE; TESTOSTERONE;

ADULT; AGED; ANDROGEN BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG ADMINISTRATION ROUTE; DRUG DOSAGE FORM; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HORMONAL REGULATION; HUMAN; MALE; MALE TYPE ALOPECIA; MAXIMUM PLASMA CONCENTRATION; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; YOUNG ADULT; ALOPECIA; BLOOD; MIDDLE AGED; NORMAL HUMAN; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADULT; ALOPECIA; DIHYDROTESTOSTERONE; FINASTERIDE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED;

EID: 84912059201     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202119     Document Type: Article

References (31)

1. Sinclair R. Male pattern androgenetic alopecia. BMJ. 1998; 317: 865-869.
2. Cash TF. The psychology of hair loss and its implications for patient care. Clin Dermatol. 2001; 19: 161-166.
3. Stough D, Stenn K, Haber R, Parsley WM, Vogel JE, Whiting DA, Washenik K. Psychological effect, pathophysiology, and management of androgenetic alopecia in men. Mayo Clin Proc. 2005; 80: 1316-1322.
4. Whiting DA. Possible mechanisms of miniaturization during androgenetic alopecia or pattern hair loss. J Am Acad Dermatol. 2001; 45 (Suppl): S81-S86.
5. Kaufman KD. Androgens and alopecia. Mol Cell Endocrinol. 2002; 198: 89-95.
6. Whiting DA. Male pattern hair loss: current understanding. Int J Dermatol. 1998; 37: 561-566.
7. Dallob AL, Sadick NS, Unger W, Lipert S, Geissler LA, Gregoire SL, Nguyen HH, Moore EC, Tanaka WK. The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab. 1994; 79: 703-706.
8. Propecia® (Finasteride) 1 mg Tablets, SmPC. http://www.medicines.org.uk/emc/history/3680/SPC/Propecia+1mg+tablets. Accessed on 20 March 2013
9. Drake L, Hordinsky M, Fiedler V, Swinehart J, Unger WP, Cotterill PC, Thiboutot DM, Lowe N, Jacobson C, Whiting D, Stieglitz S, Kraus SJ, Griffin EI, Weiss D, Carrington P, Gencheff C, Cole GW, Pariser DM, Epstein ES, Tanaka W, et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. J Am Acad Dermatol. 1999; 41: 550-554.
10. Finasteride Male Pattern Hair Loss Study Group. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol. 2002; 12: 38-49.
11. Whiting DA, Olsen EA, Savin R, Halper L, Rodgers A, Wang L, Hustad C, Palmisano J; Male Pattern Hair Loss Study Group. Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss. Eur J Dermatol. 2003; 13: 150-160.
12. Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dennatol. 2010; 146: 1141-1150.
13. Rosner W. Proscar and propecia - a therapeutic perspective. J Clin Endocrinol Metab. 2004; 89: 3096-3098.
14. Irwig MS. Persistent sexual side effects of finasteride: could they be permanent? J Sex Med. 2012; 9: 2927-2932.
15. Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med. 2011; 8: 1747-1753.
16. Propecia® (finasteride) tablets. Full prescribing information. Merck Sharp & Dohme Corp., USA. April 2012.
17. Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med. 2011; 8: 872-884.
18. Gur S, Kadowitz PJ, Hellstrom WJ. Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation. Expert Opin Drug Saf. 2013; 12: 81-90. CrossRef Published online November 22. 2012 PubMed
19. Zhang MG, Wu W, Zhang CM, Wang XJ, Gao PJ, Lu YL, Shen ZJ. Effects of oral finasteride on erectile function in a rat model. J Sex Med. 2012; 9: 1328-1336.
20. Monti D, Tampucci S, Burgalassi S, Chetoni P, Caserini M, Mailland F. Permeation and distribution of finasteride through hairless rat skin: in vitro study. [Abstract]. J Inv Dermat. 2012; 132: S104-S110.
21. Mailland F, Tampucci S, Burgalassi S, Chetoni P, Caserini M. Hair, Cutaneous Development and Stem Cell Functions. J Inv Dermat. 2012; 132: S104-S110.
22. Tampucci S, Burgalassi S, Chetoni P, Mailland F, Caserini M, Monti D. Determination of Topically Applied Finasteride Penetrated Into Hair Follicles By Using The Differential Stripping Technique. [Abstract]. J Inv Dermat. 2012; 132: S104-S110.
23. Norwood OT. In: Hair Transplant Surgery. Charles C Thomas Pub Ltd., Springfield, Illinois, USA, 1973: 3-16.
24. Phapale PB, Lee HW, Lim MS, Kim E-H, Kim S-D, Park J, Lee M, Hwang S-K, Yoon Y-R. Rapid determination of finasteride in human plasma by UPLC-MS MS and its application to clinical pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2010; 878: 1718-1723.
25. Guideline on Bioanalytical Method Validation. EMEA/CHMP/EWP/192217/2009, 21 July 2011.
26. Ohtawa M, Morikawa H, Shimazaki J. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5 alpha-androst-1-ene-17 beta-carboxamide, a new type of specific competitive inhibitor of testosterone 5 alpha-reductase, in volunteers. Eur J Drug Metab Pharmacokinet. 1991; 16: 15-21.
27. Roberts JL, Fiedler V, Imperato-McGinley J, Whiting D, Olsen E, Shupack J, Stough D, DeVillez R, Rietschel R, Savin R, Bergfeld W, Swinehart J, Funicella T, Hordinsky M, Lowe N, Katz I, Lucky A, Drake L, Price VH, Weiss D, etal. Clinical dose ranging studies with finasteride, a type 2 5α-reductase inhibitor, in men with male pattern hair loss. J Am Acad Dermatol. 1999; 41: 555-563.
28. Suzuki R, Satoh H, Ohtani H, Hori S, Sawada Y. Saturable binding of finasteride to steroid 5alpha-reductase as determinant of nonlinear pharmacokinetics. Drug Metab Pharmacokinet. 2010; 25: 208-213.
29. Frankel S. Study of the Food and Drug Administration files on Propecia: dosages, side effects, and recommendations. Arch Dermatol. 1999; 135: 257-258.
30. McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E. Finasteride, an inhibitor of 5 α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab. 1992; 74: 505-508.
31. Roehrborn CG, Lee M, Meehan A, Waldstreicher J; PLESS Study Group. Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia. Urology. 2003; 62: 894-899.